Loxo Oncology Inc  

(Public, NASDAQ:LOXO)   Watch this stock  
Find more results for LOXO
-1.90 (-2.45%)
Real-time:   2:23PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 75.26 - 78.78
52 week 25.25 - 95.92
Open 77.64
Vol / Avg. 246,333.00/489,353.00
Mkt cap 2.26B
P/E     -
Div/yield     -
EPS -5.81
Shares 29.94M
Beta 2.70
Inst. own 103%
Nov 30, 2017
Loxo Oncology Inc at Evercore ISI Biopharma Catalyst/Deep Dive Conference - 4:35PM EST - Add to calendar
Nov 14, 2017
Loxo Oncology Inc at Stifel Healthcare Conference
Nov 2, 2017
Q3 2017 Loxo Oncology Inc Earnings Release
Nov 2, 2017
Q3 2017 Loxo Oncology Inc Earnings Call - Webcast
Sep 12, 2017
Loxo Oncology Inc at Morgan Stanley Healthcare Conference - Webcast
Sep 6, 2017
Loxo Oncology Inc at Citi Biotech Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -66.54% -47.82%
Return on average equity -68.77% -50.85%
Employees 47 -
CDP Score - -


281 Tresser Blvd Fl 9
STAMFORD, CT 06901-3238
United States - Map
+1-203-6533880 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Loxo Oncology, Inc. is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company's pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. Larotrectinib, formerly referred to as LOXO-101, is an oral, selective inhibitor of the tropomyosin receptor kinase (TRK) family in development for the treatment of tumors with TRK fusions. TRK fusions have been implicated in various tumor types, such as lung cancer, head and neck cancer, melanoma, colorectal cancer, sarcoma, and breast cancer. LOXO-195 is a drug candidate in preclinical development. It was designed as a second-generation TRK inhibitor intended to address predicted acquired resistance mechanisms resulting from therapy with a first-generation TRK inhibitor, such as larotrectinib, or multikinase inhibitors with anti-TRK activity.

Officers and directors

Joshua H. Bilenker M.D. President, Chief Executive Officer, Director
Age: 45
Bio & Compensation  - Reuters
Jennifer Burstein CPA Vice President - Finance
Age: 45
Bio & Compensation  - Reuters
Jacob S. Van Naarden Chief Business Officer
Age: 32
Bio & Compensation  - Reuters
Keith T. Flaherty M.D. Director
Age: 46
Bio & Compensation  - Reuters
Lori A. Kunkel M.D. Director
Age: 59
Bio & Compensation  - Reuters
David Bonita M.D. Independent Director
Age: 41
Bio & Compensation  - Reuters
Steven A. Elms Independent Director
Age: 53
Bio & Compensation  - Reuters
Alan Fuhrman Independent Director
Age: 60
Bio & Compensation  - Reuters